Long-term treatment with aldosterone slows the progression of age-related hearing loss (Record no. 2867)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | nam a22 7a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20180321145642.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 180321b ||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | National Acoustics Laboratories |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Joshua Halonen |
| 245 ## - TITLE STATEMENT | |
| Title | Long-term treatment with aldosterone slows the progression of age-related hearing loss |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc | Age-related hearing loss (ARHL), clinically referred to as presbycusis, is one of the three most prevalent<br/>chronic medical conditions of our elderly, with the majority of persons over the age of 60 suffering from<br/>some degree of ARHL. The progressive loss of auditory sensitivity and perceptual capability results in<br/>significant declines in workplace productivity, quality of life, cognition and abilities to communicate<br/>effectively. Aldosterone is a mineralocorticoid hormone produced in the adrenal glands and plays a role<br/>in the maintenance of key ion pumps, including the Na-Kþ-Cl co-transporter 1 or NKCC1, which is<br/>involved in homeostatic maintenance of the endocochlear potential. Previously we reported that aldosterone<br/>(1 mM) increases NKCC1 protein expression in vitro and that this up-regulation of NKCC1 was not<br/>dose-dependent (dosing range from 1 nM to 100 mM). In the current study we measured behavioral and<br/>electrophysiological hearing function in middle-aged mice following long-term systemic treatment with<br/>aldosterone. We also confirmed that blood pressure remained stable during treatment and that NKCC1<br/>protein expression was upregulated. Pre-pulse inhibition of the acoustic startle response was used as a<br/>functional measure of hearing, and the auditory brainstem response was used as an objective measure of<br/>peripheral sensitivity. Long-term treatment with aldosterone improved both behavioral and physiological<br/>measures of hearing (ABR thresholds). These results are the first to demonstrate a protective effect of<br/>aldosterone on age-related hearing loss and pave the way for translational drug development, using<br/>aldosterone as a key component to prevent or slow down the progression of ARHL.<br/> |
| 773 0# - HOST ITEM ENTRY | |
| Relationship information | 336 (2016) 63e71 |
| Title | Hearing Research |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/842/Long%20term.pdf?sequence=1&isAllowed=y">https://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/842/Long%20term.pdf?sequence=1&isAllowed=y</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Universal Decimal Classification |
| Koha item type | Journal article |
No items available.